Sugi Predict

Sugi Predict / Compounds / SCHEMBL441462

SCHEMBL441462

SCHEMBL441462

CC(C)(C)SSC[C@H](N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 7/20 0.46
▸ NOS2 P35228 3/20 0.43
▸ NOS1 P29475 2/20 0.43
▸ NOS3 P29474 1/20 0.43
▸ GRIK1 P39086 2/20 0.43
▸ SLC7A5 Q01650 1/20 0.40
▸ ARG1 P05089 1/20 0.40
▸ ARG2 P78540 1/20 0.40
▸ GRIK2 Q13002 1/20 0.39
▸ PTGS1 P23219 1/20 0.38
▸ SLC7A11 Q9UPY5 1/20 0.38
▸ BHMT Q93088 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222325 1.00 KIF11 (0.46) KIF11NOS2NOS1NOS3GRIK1
SCHEMBL12438549 1.00 KIF11 (0.46) KIF11NOS2NOS1NOS3GRIK1
Water SCHEMBL6741667 0.98 KIF11 (0.45) KIF11NOS2NOS1NOS3GRIK1
Water SCHEMBL6741664 0.98 KIF11 (0.45) KIF11NOS2NOS1NOS3GRIK1
Hydrochloric Acid SCHEMBL4744896 0.98 KIF11 (0.45) KIF11NOS2NOS1NOS3GRIK1
L-Homocysteine SCHEMBL15008852 0.88 NOS2 (0.40) KIF11NOS2NOS1NOS3GRIK1
SCHEMBL15944812 0.83 NOS2 (0.33) KIF11NOS2NOS1NOS3GRIK1
SCHEMBL22280107 0.82 KIF11 (0.42) KIF11NOS2NOS1NOS3GRIK1
SCHEMBL11801814 0.82 KIF11 (0.46) KIF11NOS2NOS1NOS3GRIK1
SCHEMBL18214470 0.82 KIF11 (0.46) KIF11NOS2NOS1NOS3GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896481-B2 Modified mini-hepcidin peptides and methods of using thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-02-20 — — US claimed
US-8435941-B2 Mini-hepcidin peptides and methods of using thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-05-07 — — US claimed
EP-1679318-A1 Process for folding chemically synthesized polypeptides RMF DICTAGENE S.A. (CH) 2006-07-12 — — EP claimed
EP-1337549-B1 PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES RMF DICTAGENE SA (CH) 2006-04-05 — — EP claimed
US-20050239162-A1 Process for folding chemically synthesized polypeptides RMF DICTAGENE S.A. (CH) 2005-10-27 — — US claimed
EP-1337549-A2 PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES RMF DICTAGENE S.A. (CH) 2003-08-27 — — EP claimed
WO-2002050099-A2 PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES RMF DICTAGENE S.A. (CH) 2002-06-27 — — WO claimed
US-20020082384-A1 Process for folding chemically synthesized polypeptides RMF DICTAGENE S.A. (CH) 2002-06-27 — — US claimed
CN-114867527-B Macrocyclic peptides Herantis pharmaceutical Co. (FI) 2026-05-26 — — CN disclosed
US-12637494-B2 Method for producing peptide containing non-natural amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-05-26 — — US disclosed
EP-4737477-A2 HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS Protagonist Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
EP-4706671-A2 CONJUGATED HEPCIDIN MIMETICS Protagonist Therapeutics, Inc. (US) 2026-03-11 — — EP disclosed
US-20260062447-A1 COMPOUNDS UNIV SOUTHAMPTON (GB) 2026-03-05 — — US disclosed
US-20250360187-A1 HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE PROTAGONIST THERAPEUTICS, INC. (US) 2025-11-27 — — US disclosed
WO-2001009173-A2 USE OF QUINIC, SHIKIMIC ACIDS AND THEIR DERIVATIVES FOR PREPARING MANNOSE RECEPTOR LIGANDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNR S) (FR) 2001-02-08 — — WO disclosed
EP-0698015-A1 PREPARATION OF N-CYANODITHIOIMINO-CARBONATES AND 3-MERCAPTO-5-AMINO-1H-1,2,4-TRIAZOLE GENENTECH, INC. (US) 1996-02-28 — — EP disclosed
US-5472698-A Mixture of (N-acetyl)-L-serine, N-acetylcysteine and alpha-lipoic acid which promotes ceramide production in skin cells ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) 1995-12-05 — — US disclosed
EP-0105525-B1 THIOHYDRAZINE-1,2-DICARBONIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1986-09-10 — — EP disclosed
US-4599407-A Thiohydrazine-1,2-dicarboxylic acid derivatives and process for their preparation MAX PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1986-07-08 — — US disclosed
EP-0105525-A1 Thiohydrazine-1,2-dicarbonic acids, process for their preparation and their use Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1984-04-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062447-A1 COMPOUNDS VHL, HIF1A, HYOU1 KIF11 4745/4885NOS2 3127/4885NOS1 2501/4885
US-12637494-B2 Method for producing peptide containing non-natural amino acid MRPL21, RPL21, RPL30 KIF11 3106/4885NOS2 1815/4885NOS1 1279/4885
US-20250360187-A1 HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE HAMP, HBG1, HBG2 KIF11 4829/4885NOS2 522/4885NOS1 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.